Opioid Dose Conversion and Management

Introduction to Opioid Conversion

The American College of Physicians recommends increasing the buprenorphine sublingual dose in divided doses up to 4-16 mg daily as the primary strategy for inadequate pain control, due to its superior safety profile, including ceiling effect on respiratory depression and lower abuse potential compared to full agonists like oxycodone 1, 2

The American Pain Society suggests that if maximal buprenorphine dosing provides inadequate analgesia, a long-acting potent opioid such as extended-release oxycodone, fentanyl, morphine, or hydromorphone should be added, recognizing higher doses may be required due to buprenorphine's high binding affinity blocking other opioids from accessing mu-receptors 1
The National Comprehensive Cancer Network recommends applying a 25-50% dose reduction when switching opioids due to incomplete cross-tolerance 2

The American College of Physicians recommends continuing baseline buprenorphine during acute pain episodes and using adjuvant therapies appropriate to pain type, such as gabapentin for neuropathic pain, NSAIDs for inflammatory/musculoskeletal pain, and topical agents as indicated 4, 1, 5
The American Academy of Pain Medicine suggests using high-potency agents like hydromorphone or fentanyl for opioid rescue, recognizing higher doses may be required due to buprenorphine's receptor occupancy 2

The Substance Abuse and Mental Health Services Administration recommends verifying if a patient is on buprenorphine for opioid use disorder versus chronic pain, as sublingual formulations are FDA-approved for opioid use disorder, while transdermal patches are approved for chronic pain 5
The American Psychiatric Association suggests screening for depression and mental health conditions before finalizing long-term opioid therapy, as these significantly impact pain outcomes and substance use risk 2, 1